Abstract
This article provides a review of Lanpressun®, a new formulations of latanoprost micellar nanoemulsion without benzaltonium chloride (BAK). The pharmacokinetics and pharmacodynamics of new formulations are presented. Due to innovative delivery system and absence of detergent preseravative (BAK, poliquaternium and others) Lanpressun® possess better tolerability and safety to ocular surface, that provides patients adherence to longer therapy. The article presents the results of clinical trials demonstrating high hypotensive efficacy of Lanpressun®. Literature analysis of studies on safety and effect on ocular surface shows good tolerability of preservativefree latanoprost nanoemulsion. The authors give the assessment of Lanpressun® future perspectives in treatment of patients with openangle glaucoma
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
